SCHEMBL1759187

SCHEMBL1759187

COC(=O)c1ccc2[nH]c(=O)n(C)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
GAA P10253 3/20 0.51
HSD17B10 Q99714 2/20 0.51
PKM P14618 2/20 0.51
KMT2A Q03164 2/20 0.51
GLA P06280 1/20 0.51
HTT P42858 1/20 0.51
CASP3 P42574 1/20 0.48
LMNA P02545 1/20 0.47
PSMB8 P28062 1/20 0.47
PARP1 P09874 1/20 0.46
PGR P06401 1/20 0.46
KIF11 P52732 1/20 0.46
BRD4 O60885 1/20 0.45
B3GNT2 Q9NY97 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254017 0.88 KDM4E (0.54) CREBBPKDM4EALDH1A1HPGDGAA
SCHEMBL29996454 0.85 PGR (0.61) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL30289054 0.84 GABRA1 (0.50) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL21156818 0.83 LMNA (0.51) KMT2ALMNAPSMB8PGRKIF11
SCHEMBL1759132 0.83 B3GNT2 (0.61) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL2115896 0.82 KDM4E (0.58) CREBBPKDM4EALDH1A1HPGDGAA
SCHEMBL6763505 0.82 AURKA (0.56) LMNAPSMB8PGRB3GNT2MAOB
SCHEMBL25195141 0.81 LMNA (0.50) KDM4EALDH1A1HSD17B10LMNAPSMB8
SCHEMBL6763764 0.81 BRD4 (0.57) KDM4EALDH1A1HSD17B10LMNAPGR
SCHEMBL20529258 0.81 KMT2A (0.55) CREBBPKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630803-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2026-05-19 US disclosed
US-12540127-B2 CRBN ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 US disclosed
US-12459883-B2 Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof Kynan Duke IP, LLC (US) 2025-11-04 US disclosed
US-20240174983-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION ICAHN SCHOOL MED MOUNT SINAI (US) 2024-05-30 US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 US disclosed
EP-3717475-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2023-06-07 EP disclosed
EP-3717475-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2023-06-07 EP disclosed
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2023-05-25 US disclosed
US-20130296319-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. 2013-11-07 US disclosed
US-8507681-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2013-08-13 US disclosed
US-20130030181-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC. (US) 2013-01-31 US disclosed
US-8288405-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-10-16 US disclosed
EP-2499139-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2012-09-19 EP disclosed
EP-2499140-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2012-09-19 EP disclosed
US-20120225900-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-09-06 US disclosed
WO-2011058473-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
WO-2011058474-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174983-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION IAPP, DYRK1A, GLP1R CREBBP 1329/4885KDM4E 2871/4885ALDH1A1 3491/4885
US-12630803-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition GLP1R, DYRK1A, DYRK1B CREBBP 1612/4885KDM4E 2363/4885ALDH1A1 4351/4885
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition IAPP, GLP1R, GPR119 CREBBP 1234/4885KDM4E 2858/4885ALDH1A1 3769/4885
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB CREBBP 293/4885KDM4E 1385/4885ALDH1A1 164/4885
US-20130296319-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS ACACA, PC, ACACB CREBBP 285/4885KDM4E 1311/4885ALDH1A1 161/4885
US-12540127-B2 CRBN ligands and uses thereof CRBN, NR2C2, NR2E3 CREBBP 2302/4885KDM4E 3572/4885ALDH1A1 3395/4885
US-12459883-B2 Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof CYP8B1, HSD11B1, HSD11B2 CREBBP 446/4885KDM4E 3324/4885ALDH1A1 288/4885
US-20130030181-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB CREBBP 293/4885KDM4E 1385/4885ALDH1A1 164/4885
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF CYP8B1, HSD11B1, HSD11B2 CREBBP 446/4885KDM4E 3324/4885ALDH1A1 288/4885
US-20120225900-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS ACACA, PC, ACACB CREBBP 305/4885KDM4E 1533/4885ALDH1A1 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.